Diabetes drug reduces risk of kidney stones
Type 2 diabetes is associated with an increased risk of kidney stones, but some forms of treatment for the disease can also help reduce the risk of kidney stones.
Researchers at Mass General Brigham found that among patients with type 2 diabetes, those who started taking SGLT2 inhibitors had lower rates of kidney stones compared with patients who started taking other classes of diabetes medications. … + read more
They identify a promising biomarker for kidney health
The exclusive production of uromodulin by the kidney makes it an attractive biomarker for the study of kidney disease, which also plays an important role in hypertension. + read more
51 major kidney cell types are included in the complete kidney atlas.
It is an interactive resource for researchers and clinicians that generates hypotheses about kidney disease around the world. + read more
Jardiance being promoted as a treatment for adults with chronic kidney disease in the EU
If approved, this drug could improve the standard of care for more than 47 million Europeans with CKD and other related cardiovascular, renal and metabolic diseases. + read more
New diabetes drugs may reduce risk of kidney and respiratory diseases
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been found to reduce the risk of kidney and respiratory diseases. + read more
Early kidney protection with canagliflozin in type 2 diabetes mellitus
The results of a new clinical trial suggest that the benefits of SGLT2 inhibitors for the kidneys stem from their ability to reduce fat deposition in the organ. + read more
They create a complete 3D atlas of kidney cell organization and molecular identity in healthy and diseased kidneys.
The findings include 51 cell types, some rare and novel, in healthy kidneys and 28 cell types with characteristics associated with injury and other processes in the kidney. + read more